GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (STU:4E2) » Definitions » Institutional Ownership

Relmada Therapeutics (STU:4E2) Institutional Ownership : 11.95% (As of Apr. 29, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Relmada Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Relmada Therapeutics's institutional ownership is 11.95%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Relmada Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Relmada Therapeutics's Float Percentage Of Total Shares Outstanding is 98.48%.


Relmada Therapeutics Institutional Ownership Historical Data

The historical data trend for Relmada Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relmada Therapeutics Institutional Ownership Chart

Relmada Therapeutics Historical Data

The historical data trend for Relmada Therapeutics can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 14.27 14.58 15.32 15.31 15.38 15.46 14.28 14.17 13.13 11.95

Relmada Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Relmada Therapeutics Business Description

Traded in Other Exchanges
Address
2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Relmada Therapeutics Headlines

No Headlines